Our Science

Targeting Biomarker-Defined Cancers

Merrimack has a proven history of successfully discovering and developing novel therapeutics that have helped to shape new treatment strategies for patients. That includes the successful development and approval for ONIVYDE®1 (irinotecan liposome injection) to treat patients with advanced pancreatic cancer who have previously been treated with gemcitabine-based chemotherapy.

Today, that journey continues. Merrimack is developing a new generation of solutions for cancer through a focused pipeline of precise, targeted therapies. A cornerstone of our development strategy is to establish efficacy and value through studies in biomarker-enriched patient populations.

1ONIVYDE® was acquired by Ipsen S.A. in April 2017.

Focused Research Strategy

We are taking a systematic approach to our preclinical development work. These and other innovative programs utilizing our biomarker-driven approach will provide future opportunities to enter the clinic to help patients in need.

Preclinical Pipeline

Target
discovery
Target
validation
Lead
discovery
Lead
optimization
Pharmacologic
profiling
Ind
filing
MM-201
Ligand fusion targeting Death Receptor 4 and Death Receptor 5
Pharmacologic profiling
MM-401
Agonistic antibody targeting TNFR2
Pharmacologic profiling
Immuno-oncology

Published research & presentations

Commitment to Collaboration

Discovering and developing breakthrough cancer solutions takes a collaborative effort.
Learn more about how to work with us here.